Aetna modified CPB 0693 governing somatostatin analog coverage policy, effective September 26, 2025. Here's what billing teams need to know before claims go out the door.
Aetna, a CVS Health company, updated Clinical Policy Bulletin 0693 covering somatostatin analogs — octreotide (J2353, J2354), lanreotide (J1930, J1932), and pasireotide (J2502). The policy governs precertification requirements and site-of-care rules for these drugs across commercial plan designs. If your practice bills these HCPCS codes for neuroendocrine tumors, acromegaly, Cushing's disease, or carcinoid syndrome, this update affects your prior authorization workflow and your site-of-service documentation.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna (CPB 0693 Aetna System) |
| Policy | Somatostatin Analogs — CPB 0693 |
| Policy Code | CPB 0693 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | High |
| Specialties Affected | Oncology, Endocrinology, Gastroenterology, Neurosurgery, Hematology/Oncology |
| Key Action | Verify precertification and site-of-care documentation for J2353, J2354, J1930, J1932, and J2502 before billing commercial Aetna claims |
Aetna Somatostatin Analog Coverage Criteria and Medical Necessity Requirements 2025
The Aetna somatostatin analog coverage policy applies to four drugs: octreotide acetate (Sandostatin, Sandostatin LAR Depot), lanreotide (Somatuline or generic), pasireotide diaspartate (Signifor), and pasireotide pamoate (Signifor LAR). All four require precertification for Aetna participating providers and members in applicable commercial plan designs.
The real issue here is medical necessity documentation. Aetna will deny reimbursement if you bill J2353 (depot octreotide, 1 mg), J2354 (nondepot octreotide, 25 mcg), J1930 (lanreotide, 1 mg), J1932 (Cipla lanreotide, 1 mg), or J2502 (pasireotide long acting, 1 mg) without an approved precertification on file. This is a hard prior authorization requirement — not a soft edit you can appeal after the fact.
The covered diagnosis codes under this policy span a wide range. We're talking about 393 ICD-10-CM codes total. They include neuroendocrine tumors (C7a.00–C7a.8, D3a.00–D3a.8), pancreatic malignancies (C25.0–C25.9), GI tumors (C17.0–C19), adrenal gland cancers (C74.0–C74.12), and a broad range of other solid tumors where these drugs have established clinical utility. The coverage policy also picks up acromegaly, Cushing's disease, and variceal bleeding — conditions tied to the related CPT codes like esophagoscopy (43204) and cortisol panels (82530, 82533).
To initiate precertification, call (866) 752-7021 or fax (888) 267-3277. For Statement of Medical Necessity forms, use Aetna's Specialty Pharmacy Precertification page. Do this before the patient's first dose — not after you've already billed.
For Medicare patients, this policy does not apply. CMS governs somatostatin analog billing under separate Part B criteria. Check Aetna's Medicare Part B step therapy page for those rules.
Aetna Somatostatin Analog Site-of-Care Rules and Utilization Management
This is where the 2025 update adds a second layer of complexity. Aetna's Site of Care Utilization Management Policy applies specifically to octreotide acetate (Sandostatin LAR Depot, billed as J2353) and lanreotide (Somatuline Depot and the generic lanreotide injection, billed as J1930 and J1932).
The somatostatin analog billing question you need to answer before every claim: Is this infusion being administered in the most appropriate site of service? Aetna uses site-of-care review to steer these infusions away from hospital outpatient departments toward physician offices or home settings when clinically appropriate. A claim denial for site-of-service reasons is increasingly common for J2353 and J1930 — and it's avoidable.
The related administration codes matter here too. CPT codes 96361–96379 cover IV therapy and subcutaneous infusion. CPT 96372 covers therapeutic subcutaneous or intramuscular injections. Home infusion codes 99601–99602, along with HCPCS S9338 and S9563, also apply when these drugs go home with the patient. Your site-of-care documentation needs to support whichever setting you're billing.
If you're not sure how Aetna's site-of-care policy applies to your patient mix, talk to your compliance officer before submitting claims under the September 26, 2025 effective date.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Neuroendocrine tumors (NETs) | Covered | J2353, J2354, J1930, J1932, J2502; ICD-10 C7a.00–C7a.8, D3a.00–D3a.8 | Precertification required |
| Pancreatic malignancies | Covered | J2353, J2354, J1930; ICD-10 C25.0–C25.9 | Precertification required |
| GI malignancies (small intestine, colon) | Covered | J2353, J2354, J1930; ICD-10 C17.0–C19 | Precertification required |
| Gastric/esophageal malignancies | Covered | J2353, J2354; ICD-10 C15.3–C16.9 | Precertification required |
| Adrenal gland malignancies | Covered | J2353, J2354; ICD-10 C74.0–C74.12 | Precertification required |
| Breast cancer | Covered | J2353, J2354; ICD-10 C50.011–C50.929 | Precertification required |
| Lung/bronchial malignancies (NSCLC) | Covered | J2353, J2354; ICD-10 C33–C34.92 | Precertification required |
| Thyroid malignancy | Covered | J2353, J2354; ICD-10 C73 | Precertification required |
| Prostate cancer (hormone refractory) | Covered | J2353, J2354; ICD-10 C61 | Precertification required |
| Malignant melanoma | Covered | J2353, J2354; ICD-10 C43.0–C43.9 | Precertification required |
| Choroid/ciliary body malignancies | Covered | J2353, J2354; ICD-10 C69.30–C69.42 | Precertification required |
| Thymus malignancy | Covered | J2353, J2354; ICD-10 C37 | Precertification required |
| Cushing's disease (pasireotide) | Covered | J2502; ICD-10 E24 range | Precertification required for Signifor and Signifor LAR |
| Esophageal variceal bleeding | Covered (related procedure support) | CPT 43204, 43400, 43405 | Octreotide used acutely; precertification may apply |
| Cortisol testing (Cushing's workup) | Covered (diagnostic support) | CPT 80420, 82530, 82533 | Dexamethasone suppression panel, free and total cortisol |
| Pancreatic surgery (related procedures) | Covered (surgical context) | CPT 48150, 48152, 48153, 48154 | Pancreatectomy procedures listed as related CPT codes |
| Cardiac complex repair (Fontan-related) | Related context | CPT 33615, 33617 | Listed as related CPT codes under the CPB; verify clinical criteria |
| Home infusion / subcutaneous injection | Covered (administration) | CPT 96361–96379, 96372, 99601–99602; HCPCS S9338, S9563 | Site-of-care rules apply for J2353, J1930, J1932 |
| Everolimus combination use | Related context | HCPCS J7527 | Listed as related code; typically used in combination NET regimens |
Aetna Somatostatin Analog Billing Guidelines and Action Items 2025
These are direct steps your billing team should take before and after September 26, 2025.
| # | Action Item |
|---|---|
| 1 | Audit your precertification queue for all four drugs. Pull every open claim or upcoming order for J2353, J2354, J1930, J1932, and J2502. If you don't have an active Aetna precertification on file, call (866) 752-7021 now. Don't wait for a claim denial to find the gap. |
| 2 | Update your charge capture for site-of-care documentation. For J2353 (Sandostatin LAR Depot) and J1930/J1932 (lanreotide), your documentation must support the site of service you're billing. If you're billing in a hospital outpatient setting and home or office delivery is clinically appropriate, Aetna will flag it. Review Aetna's Site of Care Utilization Management Policy for specialty drug infusions before your next claim. |
| 3 | Pair the right administration code with the drug code. Use CPT 96372 for subcutaneous or intramuscular injections of nondepot octreotide (J2354). Use 96361–96379 for IV infusions. For home administration, bill 99601–99602 and HCPCS S9338 or S9563 as appropriate. Mismatched drug and administration codes are a common denial trigger. |
| 4 | Confirm your ICD-10 codes map to covered indications. With 393 covered diagnosis codes, most oncology and endocrinology practices will find their patients' diagnoses in scope. But verify your C7a, C25, C73, C74, and E24 codes are coded to the highest specificity before billing. Unspecified codes increase denial risk. |
| 5 | Separate commercial and Medicare workflows. This policy applies to Aetna commercial plans only. Medicare patients follow Aetna's Part B step therapy criteria — a completely different set of rules. If your billing team handles both, build a flag in your EHR or practice management system to route these claims correctly. |
| 6 | For complex combination regimens, verify everolimus separately. HCPCS J7527 (everolimus, oral, 0.25 mg) appears as a related code under CPB 0693. If you're billing octreotide or lanreotide alongside everolimus for a NET patient, confirm both drugs have active precertifications. One approval doesn't cover the other. |
| 7 | Pull the Statement of Medical Necessity form for each drug. Aetna's SMN precertification forms differ by drug. Use the correct form from Aetna's Specialty Pharmacy Precertification page. A form mismatch delays the authorization and delays your reimbursement. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Somatostatin Analogs Under CPB 0693
HCPCS Codes — Covered When Selection Criteria Are Met
| Code | Type | Description |
|---|---|---|
| J1930 | HCPCS | Injection, lanreotide, 1 mg |
| J1932 | HCPCS | Injection, lanreotide (Cipla), 1 mg |
| J2353 | HCPCS | Injection, octreotide, depot form for intramuscular injection, 1 mg |
| J2354 | HCPCS | Injection, octreotide, nondepot form for subcutaneous or intravenous injection, 25 mcg |
| J2502 | HCPCS | Injection, pasireotide long acting, 1 mg |
CPT Codes — Related to CPB 0693
| Code | Type | Description |
|---|---|---|
| 33615 | CPT | Repair of complex cardiac anomalies (e.g., tricuspid atresia) by closure of atrial septal defect |
| 33617 | CPT | Repair of complex cardiac anomalies (e.g., single ventricle) by modified Fontan procedure |
| 43204 | CPT | Esophagoscopy, flexible, transoral; with injection sclerosis of esophageal varices |
| 43400 | CPT | Ligation, direct, esophageal varices |
| 43405 | CPT | Ligation or stapling at gastroesophageal junction for pre-existing esophageal perforation |
| 48150 | CPT | Pancreatectomy, proximal subtotal with total duodenectomy, partial gastrectomy, choledochoenterostomy |
| 48152 | CPT | Pancreatectomy, proximal subtotal — without pancreatojejunostomy |
| 48153 | CPT | Pancreatectomy, proximal subtotal with near-total duodenectomy, choledochoenterostomy and duodenojejunostomy |
| 48154 | CPT | Pancreatectomy, proximal subtotal — without pancreatojejunostomy (variant) |
| 80420 | CPT | Dexamethasone suppression panel, 48-hour (includes free cortisol, urine) |
| 82530 | CPT | Cortisol; free |
| 82533 | CPT | Cortisol; total |
| 96361–96379 | CPT | IV therapy, subcutaneous infusion, therapeutic injection, and home infusion/specialty drug administration |
| 96372 | CPT | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
| 99601–99602 | CPT | Home infusion/specialty drug administration |
HCPCS Codes — Related to CPB 0693
| Code | Type | Description |
|---|---|---|
| G0069 | HCPCS | Professional services for administration of subcutaneous immunotherapy for each infusion drug administered |
| J7527 | HCPCS | Everolimus, oral, 0.25 mg |
| S9338 | HCPCS | Home infusion therapy, immunotherapy — administrative services, professional pharmacy services, care coordination |
| S9563 | HCPCS | Home injectable therapy, immunotherapy — including administrative services, professional pharmacy services |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| C15.3–C15.9 | Malignant neoplasm of esophagus |
| C16.0–C16.9 | Malignant neoplasm of stomach |
| C17.0–C19 | Malignant neoplasm of small intestine, colon, and rectosigmoid junction |
| C22.0–C22.1 | Malignant neoplasm of liver and intrahepatic bile ducts |
| C25.0–C25.9 | Malignant neoplasm of pancreas |
| C33–C34.92 | Malignant neoplasm of trachea, bronchus, and lung (non-small cell) |
| C37 | Malignant neoplasm of thymus |
| C43.0–C43.9 | Malignant melanoma of the skin |
| C4a.0–C4a.9 | Neuroendocrine tumors |
| C7a.00–C7a.8 | Malignant neuroendocrine tumors |
| D3a.00–D3a.8 | Benign neuroendocrine tumors |
| C50.011–C50.929 | Malignant neoplasm of breast |
| C61 | Malignant neoplasm of prostate (hormone refractory) |
| C69.30–C69.32 | Malignant neoplasm of choroid |
| C69.40–C69.42 | Malignant neoplasm of ciliary body |
| C73 | Malignant neoplasm of thyroid gland |
| C74.0–C74.12 | Malignant neoplasm of adrenal gland |
The full policy includes 393 ICD-10-CM codes. Review the complete list at the Aetna CPB 0693 source document before finalizing your diagnosis code mapping.
Get the Full Picture for CPT 96372
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.